Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 μg/ml in Korea

Microbial Drug Resistance

Volumn 12, Issue 1, 2006, Pages 33-38

  Kim, Hong Bin ^a,h   Lee, Yeong Seon ^a   Kim, Bong Su ^a   Cha, Jeong Ok ^a   Kwon, Sung Uk ^a   Lee, Hee Joo ^b   Suh, Jin Tae ^b   Rheem, Insoo ^c   Kim, Jeong Man ^d   Shin, Bo Moon ^e   Kim, Mi Na ^f   Lee, Kyungwon ^g   Lee, Chang Seop ^h   Kim, Eui Chong ^h,i   Oh, Myoung Don ^h,i   Choe, Kang Won ^h,i  

^a Korea National Institute of Health   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Dankook University   (South Korea)

^d Dong A University College of Medicine   (South Korea)

^e Inje University   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Seoul National University College of Medicine   (South Korea)

ⁱ Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; GLYCOPEPTIDE; VANCOMYCIN;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CATHETER INFECTION; CHILD; CHRONIC OSTEOMYELITIS; CLINICAL ARTICLE; FEMALE; HUMAN; KOREA; MALE; MEDICAL RECORD; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PENICILLIN RESISTANCE; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 33646021273     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2006.12.33     Document Type: Article

References (29)

1. Aucken, H.M., M. Warner, M. Ganner, A.P. Johnson, J.F. Richardson, B.D. Cookson, and D.M. Livermore. 2000. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. 46:639-640.
2. Centers for Disease Control and Prevention. 2002. Vancomycin-resistant Staphylococcus aureus-United States, 2002. MMWR. Morb. Mortal. Wkly. Rep. 51:565-567.
3. Centers for Disease Control and Prevention. 2002. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR. Morb. Mortal. Wkly. Rep. 51:902.
4. Centers for Disease Control and Prevention. 2004. Vancomycin-resistant Staphylococcus aureus-New York, 2004. MMWR. Morb. Mortal. Wkly. Rep. 53:322-323
5. Enright, M.C., N.P.J. Day, C.E. Davies, S.J. Peacock, and B.G. Spratt. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008-1015.
6. Feil, E.J., B.C. Li, D.M. Aanensen, W.P. Hanage, and B.G. Spratt. 2004. eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J. Bacteriol. 186:1518-1530.
7. Fluit, A.C., C.L.C. Wielders, J. Verhoef, and F.J. Schmitz. 2001. Epidemiology and susceptibility of 3051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J. Clin. Microbiol. 39:3727-3732.
8. Fridkin, S.K. 2001. Vancomycin-intermediate and resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. 32:108-115.
9. Fridkin, S.K., J.C. Hageman, L. McDougal, J. Mohammed, W.R. Jarvis, T.M. Perl, F.C. Tenover, and for the Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, Unites States, 1997-2001. Clin. Infect. Dis. 36:429-439.
10. Garner, J.S., W.R. Jarvis, T.G. Emori, T.C. Horan, and J.M. Hughes. 1996. CDC definitions for nosocomial infections. In R. N. Olmsted (ed.), APIC infection control and applied epidemiology: principles and practice. Mosby, St. Louis, pp. A1-A20.
11. Geisel, R., F.J. Schmitz, A.C. Fluit, and H. Labischinski. 2001. Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur. J. Clin. Microbiol. Infect. Dis. 20:685-697.
12. Graziani, A.M., L.A. Lawson, G.A. Gibson, M.A. Steinberg, and R.B. MacGregor. 1988. Vancomycin concentrations in infected and noninfected human bone. Antimicrob. Agents Chemother. 32:1320-1322.
13. Henwood, C.J., D.M. Livermore, A.P. Johnson, D. James, M. Warner, and A. Gardiner. 2000. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J. Antimicrob. Chemother. 46:931-940.
14. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
15. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F.C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
16. Jung, S.I., S. Kiem, N.Y. Lee, Y.S. Kim, W.S. Oh, H.L. Cho, K.R. Peck, and J.H. Song. 2002. One-point population analysis and effect of osmolarity on detection of hetero-vancomycin resistant Staphylococcus aureus. J. Clin. Microbiol. 40:1493-1495.
17. Mader, J.T., M.E. Shirtliff, S.C. Bergquist, and J. Calhoun. 1999. Antimicrobial treatment of chronic osteomyelitis. Clin. Orthop. 360:47-65
18. Munoz, P., and E. Bouza. 1999. Acute and chronic adult osteomyelitis and prosthesis-related infections. Bailliere's Best Pract. Res. Clin. Rheumatol. 13:129-147.
19. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS approved standard M7-A5. NCCLS, Wayne, PA.
20. O'Neill, G.L., S. Murchan, A. Gil-Setas, and H.M. Aucken. 2001. Identification and characterization of phage variants of a strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-15). J. Clin. Microbiol. 39:1540-1548.
21. Sahm, D.F., M.K. Marsilio, and G. Piazza. 1999. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the surveillance network database-USA. Clin. Infect. Dis. 29:259-263.
22. Sakoulas, G., P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering Jr., and G.M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
23. Schmitz, F.J., A. Krey, R. Giesel, J. Verhoef, H.P. Heinz, and A.C. Fluit. 1999. Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. Eur. J. Clin. Microbiol. Infect. Dis. 18:528-530.
24. Sieradzki, K., P. Villari, and A. Tomasz. 1998. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 42:100-107.
25. Tenover, F.C., J.W. Biddle, and M.V. Lancaster. 2001. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis. 7:327-332.
26. Tomasz, A., S. Nachman, and H. Leaf. 1991. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 35:124-129.
27. Walsh, T.R., and R.A. Howe. 2002. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56:657-675.
28. Walsh, T.R., A. Bolmstrom, A. Qwarnstrom, P. Ho, M. Wootton, R.A. Howe, A.P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.
29. Walsh, T.R., M. Wootton, R.A. Howe, P.M. Bennett, and A.P. MacGowan. 1999. Increased biofilm formation and adherence to artificial surfaces of hVISA on exposure to vancomycin. In Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 44, American Society for Microbiology, Washington, DC, p. 91.